Results 131 to 140 of about 39,307 (247)

Metastatic Unfunctional Pancreatic Neuroendocrine Tumor in Lynch Syndrome

open access: yesClinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Lynch syndrome (LS), a well‐known cancer risk syndrome, is caused by deleterious germline mutations in the mismatch repair genes. LS predispose patients to various types of cancers including colon adenocarcinoma. We discuss the case of a woman with LS who also developed a non‐functioning pancreatic neuroendocrine tumor (P‐NET) following ...
Fateme Salemi   +5 more
wiley   +1 more source

Sutural cataract in neurofibromatosis type 1

open access: yesIndian Journal of Ophthalmology. Case Reports, 2023
Athul S Puthalath   +2 more
doaj   +1 more source

Robotic resection for splenic artery aneurysm associated with neurofibromatosis type 1: a case report

open access: yesJournal of Medical Case Reports
Background Neurofibromatosis type 1 is an autosomal-dominant disease characterized by café-au-lait spots and neurofibromas, as well as various other symptoms in the bones, eyes, and nervous system.
Akihiko Ueda   +9 more
doaj   +1 more source

A rare case of neurofibromatosis type 1

open access: yes, 2016
Neurofibromatosis type 1 disease is characterized by pigmented cutaneous lesions and generalized tumors of neural crest origin. Sphenoid dysplasia is one of the characteristics of this syndrome which occurs in 5-10% of the cases.
Vijaya Prasad Balda   +2 more
core   +1 more source

Solitary Nodule in the Hard Palate

open access: yes
Oral Diseases, EarlyView.
Sara Lia Gonçalves de Lima   +6 more
wiley   +1 more source

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 274-285, July 2026.
BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Natalia Sauer   +3 more
wiley   +1 more source

Neurofibromatosis type 1

open access: yesMuller Journal of Medical Sciences and Research, 2013
P Chaitra, M Ramesh Bhat
doaj   +1 more source

SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype

open access: yes, 2009
International audienceGermline loss-of-function mutations in the gene have recently been identified in patients fulfilling the National Institutes of Health (NIH) diagnostic criteria for neurofibromatosis type 1 (NF1) but with no (neurofibromin 1 ...
Sabbagh, Audrey   +14 more
core   +1 more source

Attrition in Cochlear Implant Research: Sociodemographic, Audiologic, and Performance Variables

open access: yesThe Laryngoscope, Volume 136, Issue 7, Page 3195-3202, July 2026.
In a retrospective review of attrition patterns for participants in a clinical research study, sociodemographic variables were not significantly different between those who elected to withdraw and those who completed the study. Those in the withdrawal group had poorer low‐frequency residual hearing, were less likely to be electric‐acoustic stimulation ...
Amanda D. Sloop   +5 more
wiley   +1 more source

Multimodal Imaging Characteristics and Diagnostic Value of Choroidal Nodules in Patients with Neurofibromatosis Type 1 [PDF]

open access: yes
Objectives: Yasunari nodules are choroidal lesions observed in patients diagnosed with neurofibromatosis type 1 (NF-1) and characterized by relatively irregular dome-shaped, plaque-like, or patchy boundaries.
Mustafa Kayabaşı   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy